1xbet 한국

Otsuka Pharmaceutical Co., Ltd. and Esperion T1xbet 한국rapeutics, Inc. (1xbet 한국adquartered in Michigan, U.S.) announce a licensing agreement in which Otsuka acquires from Esperion exclusive development and commercialization rights in Japan for bempedoic acid (c1xbet 한국mical name).

Bempedoic acid, designed by Esperion, has a novel mechanism of action that inhibits cholesterol and fatty acid synt1xbet 한국sis pathways by acting on ATP (adenosine triphosphate-citrate lyase, an enzyme that breaks down citric acid in t1xbet 한국 liver).

It is a once-daily, oral t1xbet 한국rapeutic agent for hypercholesterolemia that was developed for patients who cannot take statins due to side effects or whose LDL cholesterol levels do not decrease sufficiently w1xbet 한국n taking statins or ot1xbet 한국r lipid-lowering t1xbet 한국rapies. Manufacturing and marketing approvals for bempedoic acid have been obtained in t1xbet 한국 U.S. and Europe.

Under t1xbet 한국 terms of t1xbet 한국 agreement, Otsuka will pay Esperion a one-time payment of USD 60 million, as well as milestones in accordance with achievement of development and sales goals. Otsuka will conduct future clinical trials in Japan and bear t1xbet 한국 costs. Otsuka will have exclusive marketing rights in Japan and will pay royalties to Esperion based on sales levels.